Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCannara Biotech Inc.

Cannara Biotech Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
2.12 CAD 0.04 ( 1.92%)
Last update at 2026-11-06T20:14:00Z
VOLUME
70058
Market Cap
172.87M
P/E
15.91

Momentum Score

…

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.04
Low
2.17
High
52 Week Price Range
1.67
Low
2.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cannara Biotech Inc. is a publicly listed Canadian company with limited recent public disclosures, which restricts definitive statements about its core operations. The company appears positioned in the cannabis/hemp cultivation and processing sector and may benefit from longer-term trends such as regulatory normalization, product diversification and scale economies. Investors may find the company attractive if it establishes consistent revenue growth, demonstrates operational scale and secures reliable access to capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.08
Dividend Yield
-
Revenue TTM
113.01M
Revenue Per Share
1.21
Gross Profit TTM
48.00M
Debt / Equity
0.41
ROE
9.48%
Net Debt
27.22M
ROCE
16.19%
Diluted EPS TTM
0.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax 18.10M 4.48M 6.95M 2.31M -1.53M
Net income 13.08M 6.44M 6.95M 2.31M -3.09M
Selling general administrative 13.33M 12.97M 10.61M 8.59M 6.16M
Selling and marketing expenses 9.84M 6.68M 2.91M 1.44M 1.14M
Gross profit 47.22M 29.79M 27.23M 17.33M 10.30M
Reconciled depreciation 6.68M 6.35M 4.94M 3.92M -
Ebit 21.77M 8.81M 10.83M 5.62M 0.20M
Ebitda 28.18M 15.16M 15.77M 9.54M 3.22M
Depreciation and amortization 6.40M 6.35M 4.94M 3.92M 3.03M
Operating income 22.20M 10.08M 11.89M 3.67M 0.19M
Other operating expenses 85.12M 71.67M 45.37M 30.87M 16.72M
Interest expense 4.35M 5.66M 5.30M 3.31M 1.73M
Tax provision 5.02M -1.95M 0.00M - -
Interest income 0.28M 0.18M 0.24M 0.09M -
Net interest income -4.10M -5.47M -5.01M -3.22M -
Income tax expense 5.02M -1.95M - -0.55M 1.57M
Total revenue 107.32M 81.75M 57.26M 35.84M 17.02M
Total operating expenses 25.02M 19.71M 15.34M 12.36M 10.00M
Cost of revenue 60.10M 51.96M 30.03M 18.51M 6.72M
Total other income expense net -4.10M -5.59M -4.94M -2.64M -1.79M
Net income from continuing ops 13.08M 6.44M 6.95M 2.31M -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 168.65M 154.72M 141.52M 125.62M 92.02M
Other current assets 9.18M 7.74M 3.06M 1.28M 0.71M
Total liab 66.43M 66.77M 61.78M 58.88M 27.91M
Total stockholder equity 102.22M 87.95M 79.74M 66.74M 64.12M
Other current liab 9.68M 7.88M 5.04M 0.77M 0.07M
Common stock 89.76M 88.52M 88.80M 83.30M 83.21M
Capital stock 89.76M 88.52M 88.80M 83.30M -
Retained earnings 0.18M -12.90M -19.34M -26.30M -28.61M
Cash 14.36M 6.62M 4.27M 12.11M 8.16M
Total current liabilities 34.20M 27.00M 21.18M 11.86M 6.83M
Current deferred revenue 0.13M 0.13M 0.16M 0.05M 0.04M
Net debt 27.22M 41.71M 41.51M 36.28M 12.74M
Short term debt 13.30M 9.50M 6.04M 2.19M 0.53M
Short long term debt 13.02M 9.23M 5.97M 1.97M -
Short long term debt total 41.58M 48.33M 45.78M 48.39M 20.90M
Other stockholder equity 12.28M 12.33M 10.35M 9.72M 9.41M
Total current assets 82.16M 67.47M 51.70M 40.99M 19.25M
Net receivables 14.11M 13.04M 10.59M 8.62M 2.97M
Long term debt 28.17M 38.45M 39.64M 46.19M -
Inventory 44.52M 40.07M 33.77M 18.98M 7.41M
Accounts payable 11.08M 1.96M 8.89M 8.53M 6.19M
Accumulated other comprehensive income - - -0.07M 0.02M 0.10M
Non currrent assets other 0.49M 0.26M 0.31M 0.30M 0.40M
Non current assets total 86.49M 87.25M 89.83M 84.63M 72.78M
Capital lease obligations 0.40M 0.65M 0.18M 0.24M -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total cashflows from investing activities -5.95M -5.19M -9.48M -15.35M -30.83M
Net borrowings -2.58M 1.03M 0.76M -34.30M -
Total cash from financing activities -6.32M -3.14M -3.72M 25.46M 33.25M
Net income 13.08M 6.44M 6.95M 2.31M -1.53M
Change in cash 7.74M 2.35M -7.84M 3.96M 0.39M
Begin period cash flow 6.62M 4.27M 12.11M 8.16M 7.77M
End period cash flow 14.36M 6.62M 4.27M 12.11M 8.16M
Total cash from operating activities 20.01M 10.68M 5.44M -6.08M -2.09M
Issuance of capital stock - - - 0.00M -
Depreciation 6.68M 6.35M 4.94M 3.92M 3.03M
Other cashflows from investing activities 0.41M 2.28M 0.40M 0.06M 0.03M
Dividends paid 0.00M 0.00M 0.00M 0.00M -
Change to inventory 9.08M -3.98M -8.33M -8.23M -3.35M
Change to account receivables -1.04M -2.06M -2.05M -5.68M -2.82M
Sale purchase of stock 0.00M -0.28M -0.37M 0.00M -
Other cashflows from financing activities -4.09M -3.90M -1.10M -2.14M -1.13M
Capital expenditures 6.36M 7.47M 9.88M 15.47M 31.07M
Change in working capital -6.30M -2.50M -6.11M -11.48M -3.82M
Stock based compensation 1.19M 1.98M 1.75M 0.35M 0.33M
Other non cash items 5.36M 0.37M -2.09M -1.17M -0.17M
Free cash flow 13.65M 3.21M -4.44M -21.55M -33.17M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LOVE
Cannara Biotech Inc.		 0.04
1.92%		 2.12 15.91 14.58 1.53 1.44 1.64 7.60
CURA
Curaleaf Holdings Inc.		 0.11
0.83%		 13.33 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.77%		 11.50 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 -0.13
2.49%		 5.10 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.20
5.09%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Cannara Biotech Inc.

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.

333 Decarie Blvd., Saint-Laurent, QC, Canada, H4N 3M9

514 543 4200

https://cannara.ca

452

Name Title Year Born
Mr. Zohar Krivorot Founder, CEO & Chairman 1977
Mr. Nicholas Sosiak C.A., CPA Chief Financial Officer NA
Mr. Avi Krivorot Chief Technology Officer NA
Mr. Brian Sherman General Counsel & VP Legal Affairs NA
Scott Carroll Vice President of Commercial Strategy & Marketing NA
Nick Van Dam Vice President of Sales NA
Ms. France Landry Vice President of Human Resources NA
Etienne Ledoux Executive Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…